The EVOLUTION HF study aimed to report real-world characteristics and treatment patterns in patients who received dapagliflozin following hospitalized heart failure, an area with minimal clinical data. In this touchCARDIO interview, we speak with Dr Gianluigi Savarese (Karolinska University Hospital, Stockholm, Sweden) to discuss the limitations of current guideline-directed medical therapies in patients with heart failure (HF) with reduced ejection fraction (HFrEF)aims and findings of the EVOLUTION HF study
The abstract entitled ‘Dapagliflozin utilization following hospitalization for heart failure: real-world insights from EVOLUTION HF, a multinational, observational study’ was presented at the European Society of Cardiology (ESC) Congress 2022, 26 – 29 August 2022.
- What are the limitations of current guideline-directed medical therapies in patients with heart failure (HF) with reduced ejection fraction (HFrEF)? (0:35)
- What is known about the impact of dapagliflozin on HF outcomes in patients with HFrEF? (1:26)
- What were the aims and design of the EVOLUTION HF study? (2:56)
- What did the study teach us about dapagliflozin utilization following hospitalization for heart failure? (3:46)
- What is the key take home message of these findings? (4:53)
Disclosures: The study has been supported by AstraZeneca.
Support: Interview and filming supported by Touch Medical Media. Interview conducted by Danielle Crosby.
Filmed as a highlight of ESC 2022
Access more content on Heart Failure here
Share this Video
Related Videos In Heart Failure
ESC Congress 2023 Amsterdam: Ross Campbell, OPERA-AI trial, handheld echocardiography in suspected heart failure
Presented at the European Society of Cardiology Congress (ESC Congress) 2023 Amsterdam, the OPERA-AI trial compared the use of handheld echocardiography analysed by artificial intelligence (AI) to ‘cart-based’ echocardiography reported by humans, to help diagnose suspected heart failure. In this touchCARDIO interview, we speak to Dr. Ross Campbell (University of Glasgow, Glasgow, UK) to discuss the […]
ESC Congress 2023 Amsterdam: Robert Mentz, HEART-FID trial, intravenous iron for heart failure with reduced ejection fraction
The HEART-FID trial built on research from the AFFIRM-AHF and IRONMAN trials to investigate the use of intravenous iron in treating heart failure with iron deficiency. In this touchCARDIO interview, we speak to Dr. Robert Mentz (Duke University, NC, US) regarding the HEART-FID trial, presented at the European Society of Cardiology Congress (ESC Congress) 2023 […]
Gregg Stone, ACC 2023: COAPT trial results – Transcatheter edge-to-edge repair with MitraClip device for functional mitral regurgitation in heart failure
The COAPT trial investigated the use of the MitraClip a novel device for patients with secondary mitral regurgitation, a condition in which blood leaks backward through the mitral valve into the left atrium of the heart. In this touchCARDIO interview Dr Gregg Stone (Mount Sinai Heart Health System, New York City, NY, USA) discusses the […]
Journal articles and more to your inbox
Get the latest clinical insights from touchCARDIOSign me up!